Methods

Data were pooled from the TOMORROW trial⁴ and two INPULSIS trials⁵ in which subjects were randomized to receive nintedanib or placebo.
The occurrence of progression events over the 52-week treatment period plus 7 days was analyzed post-hoc.
Progression events were defined as:

Events of the same type on different dates were counted as separate events. Different types of event on the same date were counted as one event.